ClinicalTrials.gg

Program

ABBV-6628

A development code.

In AbbVie's pipeline, C5. Its studies are mostly in Geographic Atrophy, led by AbbVie.

Furthest: phase 2, since Aug 12, 20251 company-led study, 1 open or runningNext primary completion: Oct 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie11 open or runningphase 2since Aug 12, 2025Aug 12, 2025Oct 2029phase 2 · NCT07160179
  • Named in AbbVie’s own pipeline as ABBV-6628, phase 1, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 12, 2025First study: phase 2 study in Geographic AtrophyFirst studyNCT07160179 · 66 planned · United States

Ahead

  1. Oct 2029Primary completion: phase 2 study in Geographic AtrophyNCT07160179

TargetBeta

“C5”the company's pipeline, read by Claude · source

Other programs on C5

ProgramCompanyFurthest phaseStudies
eculizumabruleAstraZenecaphase 438
ravulizumabruleAstraZenecaphase 435
pozelimabruleRegeneron Pharmaceuticalsphase 414
zilucoplanruleUCBphase 314
vilobelimabruleinflarx-gmbhphase 313
CrovalimabruleHoffmann-La Rochephase 310
cemdisiranruleRegeneron Pharmaceuticalsphase 310

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07160179Geographic Atrophy · United States2RecruitingOct 202966

How it is read

Names in the registry

  • “ABBV-6628”, 1 entry

Codes read as this program: ABBV6628.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.